• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Academy
  • FAQ
  • News
  • Blog
  • Europe
    • United Kingdom
    • Spain
    • Italy
    • Portugal
    • Brazil
    • Colombia
    • Ecuador
    • Mexico
    • Argentina
    • Latin America
    • UAE
Veritas

Veritas

  • Services and Test
        • Preventive Medicine
        • Pregnancy & Early Childhood
        • Diagnostic Genetics Services
        • Genetic Counselling
  • Medical Professionals
  • Partners
  • Experiences
  • About Veritas
  • CONTACT
LlámanosLlámanos
CALL US!
  • Europe

  • United Kingdom

  • Spain

  • Italy

  • Brazil

  • Portugal

  • Colombia

  • Ecuador

  • Mexico

  • Argentina

  • Latin America

  • Services & Test
    • Preventive Medicine
      • myGenome
      • myGeneticRisk
      • myHealthScore
    • Pregnancy & Early Childhood
      • myPrenatal
      • myNewborn
      • myBabyHealth
      • myPrenatal WES
    • Genetics Diagnostics
      • myCardio
      • myCancerRisk
      • GenomeDx
      • ExomeDx
      • myDiagnostic
    • Genetic Counseling
  • Medical Professionals
  • Partners
  • Experiences
  • About Veritas
  • Academy
  • FAQ
  • News
  • Blog
  • Contact

myNewborn

myNewborn

Comprehensive newborn genetic screening for early onset diseases

myNewborn offers early screening for genetic diseases that appear during the first stages of life, providing key information for preventive management, diet or early treatment. The test complements the conventional heel prick test, improving clinical utility.

The test is indicated for newborns and children in the first years of life who do not present symptoms of genetic disease and is performed on blood or by buccal scraping with a specific device provided by Veritas.

myNewborn is key to personalise medical management from day one.

Significantly amplifies newborn screening procedures, such as the required heel prick test​

Allows to prevent the development of many diseases​

Based on findings from the BabySeq project​

For healthy babies​

Selection of diseases

The test performs whole exome sequencing and subsequent analysis of more than 400 genes related to more than 390 metabolic and genetic diseases of early childhood onset.

The diseases have been included based on the following criteria:

  • Highly actionable with onset during infancy.
  • Included in the biochemical newborn screening test.
  • With adult onset, but where intervention is possible during childhood.
  • With a carrier frequency greater than 1/100 even if untreated, with the aim of knowing the prognosis and making informed decisions for future pregnancies.

The diseases are classified into different groups including:

  • Metabolic
  • Syndromic​
  • Pulmonary
  • Musculoskeletal 
  • Hematologic
  • Endocrine
  • Neurological
  • Cardiovascular ​
  • Deafness
  • Immunological
  • Cancer
  • Urogenital

The intervention to these diseases can be performed through the following types of management:

  • Preventive management ​
  • Early management ​
  • Dietary management 
  • Other types of intervention​

myNewborn clinical application examples

Pathology

Symptomatology

Patient Management

Result

G6PD Deficiency
Glucose-6-Phosphate Dehydrogenase.

Hemolytic anemia when beans, sulfites, specific drugs or food colorings are consumed.

Dietary modification avoiding specific foods and drugs.

Child without symptomatology.

Familial hypercholesterolemia (LDLR).

People with mutations in this gene can present early cardiovascular diseases since infancy.

Dietary modification and medication.

Prevention of cardiovascular disease.

Supravalvular aortic stenosis
(ELN gene).

Aortic narrowing that can lead to the collapse of the patient.

Patient monitoring and when need, perform surgical procedure to widen aortic lumen.

Prevention of patient collapse.

Alport syndrome
(COL4A5, COL4A3, COL4A4 genes).

Increased risk of kidney failure due to collagen alteration.

Monitoring and pharmacological treatment when kidney function is reduced.

Maintenance of kidney function.

Are you interested in myNewborn but you do not have a doctor that provides the service?

Our medical professionals can help you. Please click on the below button to learn more.

FIND OUT MORE
PATIENT BROCHURE

Are you interested in offering myNewborn from Veritas?

Contact us and find out how we can work together.

CONTACT US
MEDICAL BROCHURE

Advantages of myNewborn

myNewborn is an extension of routine neonatal biochemical screening, increasing the number of metabolic and genetic diseases analysed for intervention through nutrition or other procedures during early infancy, improving the health of the newborn.

Requires a routine blood sample, cord blood or buccal swab collected with a kit provided by Veritas.

Analyses the newborn’s DNA using advanced sequencing technology which provides reliable results.

myNewborn is for any baby without disease symptoms as part of the medical care.

BabySeq project provided key data on genetic diseases in newborns, revealing that around 10% of the babies tested had genetic alterations that increased the risk of developing a childhood-onset disease. Th­is project, based on newborn genome sequencing, and funded by the U.S. government, aims to integrate genomics into clinical practice for both healthy and ill neonates.

Advice to the specialist

Veritas offers a differential service by providing advice to the specialist for the interpretation of your patient’s results, whenever you need it.

Are you a medical professional?

If you want more technical information about myNewborn you can download the medical brochure here.

Recurso 27

DOWNLOAD

Frequently asked questions about myNewborn

How does the myNewborn test work?

myNewborn is a genetic sequencing test that is performed from a simple saliva sample. We sequence the entire exome (Whole Exome Sequencing) and issue a results report, the impact of which must be assessed by a specialist. All our tests must be prescribed by a doctor, and include pre and post test genetic counseling.

Is myNewborn suitable for all ages?

myNewborn is a test that is designed for children from the moment of birth, to know the risk of early-onset genetic diseases. The sooner the test is performed, the sooner the child can benefit from the findings.

SEE ALL QUESTIONS

Footer

  • facebook
  • youtube
  • twitter
  • instagram
  • linkedin

VERITAS INTERCONTINENTAL – Pº DE LA CASTELLANA 101 – BAJO 1, 28046 MADRID, ESPAÑA – CIF B88132907 – CENTRO MÉDICO AUTORIZADO Registro Nº CS15664

  • Privacy policy and Legal notice
  • General contracting conditions
  • Cookies Policy